Cerivastatin modulates antiatherogenic properties of high-density lipoproteins in patients with coronary heart disease and hyperlipidemia.
The effects of cerivastatin on antiatherogenic properties of high-density lipoproteins were studied in patients with coronary heart disease and hyperlipidemia. Apart from hypolipidemic effects, cerivastatin changed the phospholipid composition of high-density lipoproteins and improved their cholesterol-acceptor properties. This effect was most pronounced in the serum from patients with low content of high-density lipoprotein cholesterol. These data indicate that cerivastatin modulates antiatherogenic properties of high-density lipoproteins.
Ozerova
I N
IN
Department of Metabolic Disorders, Research Center of Preventive Medicine, Russian Ministry of Health, Moscow.
Jeevan
D M
DM
Serdyuk
A P
AP
Paramonova
I V
IV
Akhmedzhanov
N M
NM
Metel'skaya
V A
VA
Perova
N V
NV
D000328:Adult; D000368:Aged; D001161:Arteriosclerosis / Q000517:prevention & control*; D002784:Cholesterol / Q000097:blood; D003327:Coronary Disease / Q000097:blood* / Q000188:drug therapy; D004311:Double-Blind Method; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood* / Q000188:drug therapy; D008075:Lipoproteins, HDL / Q000097:blood / Q000737:chemistry / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D010743:Phospholipids / Q000097:blood / Q000737:chemistry; D011725:Pyridines / Q000494:pharmacology*
D008075:Lipoproteins, HDL; D010743:Phospholipids; D011725:Pyridines; D002784:Cholesterol; C086276:cerivastatin